Phase II trial of dose dense neo-adjuvant gemcitabine, epirubicin, ABI-007 [paclitaxel] (GEA) in locally advanced or inflammatory breast cancer.

Trial Profile

Phase II trial of dose dense neo-adjuvant gemcitabine, epirubicin, ABI-007 [paclitaxel] (GEA) in locally advanced or inflammatory breast cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2013

At a glance

  • Drugs Epirubicin; Gemcitabine; Paclitaxel; Pegfilgrastim
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 May 2011 Celgene Corporation as company and lead trial centre added as reported by ClinicalTrials.gov.
    • 23 Jun 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
    • 23 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top